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Spinal muscular atrophy (SMA) is the second most com-
mon genetic cause of death in childhood. However, no 
effective treatment is available to halt disease progres-
sion. SMA is caused by mutations in the survival motor 
neuron 1 (SMN1) gene. We previously reported that 
PTEN depletion leads to an increase in survival of SMN-
deficient motor neurons. Here, we aimed to establish the 
impact of PTEN modulation in an SMA mouse model 
in vivo. Initial experiments using intramuscular delivery 
of adeno-associated vector serotype 6 (AAV6) expressing 
shRNA against PTEN in an established mouse model of 
severe SMA (SMNΔ7) demonstrated the ability to ame-
liorate the severity of neuromuscular junction pathology. 
Subsequently, we developed self-complementary AAV9 
expressing siPTEN (scAAV9-siPTEN) to allow evaluation 
of the effect of systemic suppression of PTEN on the 
disease course of SMA in vivo. Treatment with a single 
injection of scAAV9-siPTEN at postnatal day 1 resulted in 
a modest threefold extension of the lifespan of SMNΔ7 
mice, increasing mean survival to 30 days, compared to 
10 days in untreated mice. Our data revealed that sys-
temic PTEN depletion is an important disease modifier 
in SMNΔ7 mice, and therapies aimed at lowering PTEN 
expression may therefore offer a potential therapeutic 
strategy for SMA.
Received 20 August 2014; accepted 21 October 2014; advance online  
publication 6 January 2015. doi:10.1038/mt.2014.209
INTRODUCTION
The characteristic neuromuscular defects observed in spinal mus-
cular atrophy (SMA) result primarily from the death of motor 
neurons in the anterior horn of the spinal cord. SMA is caused by 
mutations or deletion of the telomeric copy of the survival motor 
neuron 1 gene (SMN1) which results in reduced SMN protein 
levels.1,2 SMN is ubiquitously expressed and is involved in many 
aspects of RNA metabolism.3 It therefore remains unclear exactly 
why SMN deficiency predominantly affects motor neurons.4 One 
distinctive feature of SMN-deficient motor neurons is an axon 
elongation defect, which has been reported in cultured cells,5 as 
well as in zebrafish embryos with reduced SMN levels.6 In the 
growth cones of Smn-deficient murine motor neurons, reduced 
β-actin protein and mRNA levels were also observed.7 This sug-
gests that SMN may be necessary for mRNA transport along 
axons. Moreover, neuromuscular junction (NMJ) defects have 
been widely reported in a range of animal models of SMA.7–10
We and others have reported that restoring SMN expression11 
rescues early lethality in a well-characterized mouse model of 
disease, and this is clearly a promising therapeutic approach for 
SMA. However, modulating the expression of other genes might 
provide additional motor neuron protection through alterna-
tive mechanisms and molecular pathways. For example, cardiac 
defects have been reported in a range of animal models of SMA, 
the severity of which may not be directly related to SMN lev-
els.12–14 We have therefore focused our attention on the potential 
for PTEN knockdown to ameliorate disease pathology in SMA, 
since we first reported that experimental targeting of PTEN 
increases neuronal survival following ischemic injury in vitro and 
in vivo.15 Our recent studies have revealed that PTEN depletion in 
cultured Smn-deficient murine motor neurons ameliorates axon 
outgrowth defects, increases growth cone size, and improves cell 
survival.16 PTEN negatively regulates the proliferation and size of 
neural stem cells as well as promoting apoptosis.17 This protein 
exerts its role through the negative regulation of the PI3K/PKB/
Akt signaling pathway.18 It is expressed in the mouse brain during 
late development and is preferentially expressed in neurons in the 
adult brain.19 The PTEN protein is also enriched in cell bodies and 
axon terminals of purified motor neurons.16 Depletion of PTEN 
promotes regeneration of axons in adult retinal ganglion cells and 
neurites of cortical neurons.20,21
Our previous study using focal intramuscular injection of 
AAV6-siPTEN to silence PTEN in mice in vivo has demonstrated 
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successful knockdown of PTEN levels in SMA animals, as well 
as successful targeting of motor neurons in the ventral horn 
of the spinal cord.16 Here, we initially extended our findings to 
show that intramuscular injection of AAV6-siPTEN can amelio-
rate NMJ pathology in SMA mice. We then sought to establish 
whether silencing PTEN across a broader range of cellular targets 
could ameliorate the overall SMA phenotype in mice. We there-
fore generated a scAAV9-siPTEN vector and administered it by 
intravenous injection to neonatal SMNΔ7 mice to achieve wide-
spread knockdown of PTEN expression. This treatment improved 
the motor function of SMA mice and significantly extended their 
lifespan. Histological analysis showed that intravenously adminis-
tered AAV9 can mediate significant transduction efficiency11,22 in 
the spinal cord, correlating with a significant reduction in PTEN 
protein level.
RESULTS
AAV6-mediated PTEN silencing improves NMJ 
innervation
Given our previous encouraging data showing that PTEN deple-
tion leads to an increase in survival of SMN-deficient motor neu-
rons in vitro and that injection of adeno-associated virus serotype 
6 (AAV6) expressing siPTEN into hind limb muscles of mice is 
capable of targeting PTEN expression in spinal cord motor neu-
rons,16 we first wanted to examine whether local targeting of PTEN 
with AAV6 could rescue effects on muscle denervation in SMA. 
Previous studies have identified loss of nerve/muscle connectivity 
at the NMJ as one of the earliest and most important pathological 
events in SMA.23,24 We therefore examined the effect of targeting 
PTEN on NMJ pathology in SMN2+/+; SMNΔ7+/+; Smn-/- (SMNΔ7) 
mice, a well-characterized model of SMA.25 We injected 1010 vec-
tor genome of AAV6-siPTEN (n = 4 mice) or AAV6-scrambled-
siPTEN (n = 4 mice) vectors into the levator auris longus (LAL) 
muscle of postnatal day 1 SMNΔ7 mice. The LAL muscle was 
chosen for these experiments as it has a caudal band where 
NMJ pathology is very pronounced in SMA mice, alongside a 
rostral band where NMJ pathology is almost entirely absent.23,26 
Qualitative assessment of NMJs in the caudal band of the muscle 
suggested a decrease in the numbers of denervated NMJs in the 
AAV6-siPTEN tissue compared to AAV6-scrambled-siPTEN tis-
sue (Figure 1a). Quantitative analysis of NMJ integrity revealed a 
significant increase in the numbers of innervated motor endplates 
in the AAV6-siPTEN–treated muscles (Figure 1b). Importantly, 
AAV6-siPTEN treatment had no effect on the remaining healthy 
NMJs located in the rostral band of the muscle (Figure 1b), sug-
gesting that reducing PTEN expression was well tolerated by 
healthy motor neurons.
scAAV9-siPTEN improves survival and phenotype of 
the SMNΔ7 mouse model
To explore the possibility that systemic PTEN reduction might 
improve survival in SMA, we developed self-complementary 
adeno-associated virus serotype 9 expressing RNA interference 
against PTEN (scAAV9-siPTEN; see Materials and Methods). 
We injected 10 µl (1010 vector genome) of scAAV9-siPTEN (n = 
10) or scAAV9-scrambled-siPTEN (n = 10) vectors systemically 
into the facial vein of postnatal day 1 SMNΔ7 mice. As additional 
controls, we included untreated SMNΔ7 (n = 9) and SMN2+/+; 
SMNΔ7+/+; Smn+/- (carrier) mice (n = 6) in the study. scAAV9-
siPTEN–injected mice showed gradual gain of body weight which 
continued to increase, whereas the weight of scAAV9-scrambled-
siPTEN and untreated SMNΔ7 controls began to fall from post-
natal day 9 (Figure 2b). The body weight of scAAV9-siPTEN mice 
became significantly greater than that of scAAV9-scrambled-siP-
TEN group from day 11 onward. The body weight of scAAV9-
siPTEN–injected mice continued to slowly increase throughout 
their life but remained approximately half the weight of carrier 
littermates (Figure 2b).
Injection of scAAV9-siPTEN resulted in a significant increase 
in lifespan, with 60% of injected mice surviving longer than 
any scAAV9-scrambled-siPTEN–injected mice (Figure 2d, 
Supplementary Videos S1 and S2). Mean survival for scAAV9-
siPTEN–injected mice was 30.4 ± 7.4 days with the longest surviv-
ing mouse living for 74 days. In comparison, there was a mean 
survival of 9.2 ± 1.5 and 10.56 ± 1.42 days for scAAV9-scrambled-
siPTEN and untreated SMNΔ7 mice, respectively (Figure 2d, 
Figure 1 scAAV6-mediated knockdown of PTEN ameliorates neuro-
muscular junction (NMJ) pathology in SMA mice. (a) Representative 
confocal micrographs showing widespread NMJ pathology in the cau-
dal band of the levator auris longus muscle (LAL) in SMNΔ7 mice at 
postnatal day 10 that received intramuscular injection of scrambled 
siPTEN (AAV6-ssiPTEN) at postnatal day 1 (left panel) and reduced 
pathology in mice that received intramuscular injection of siPTEN (AAV6-
siPTEN). Antibodies against neurofilament proteins were used to label 
motor axon collaterals (green), and tetramethylrhodamine-conjugated 
α-bungarotoxin was used to label acetylcholine receptors at the motor 
endplate (red). More motor endplates appeared to be innervated by 
overlying motor nerve terminals in the AAV6-siPTEN–treated muscle. 
(b) Bar chart showing the extent of NMJ denervation (mean ± SEM) in 
the affected caudal band, and unaffected rostral band, of the LAL muscle 
in treated (siRNA) and untreated (ssiRNA) mice. This analysis revealed 
significantly more innervated NMJs in the caudal band of treated mice 
(*P < 0.05, n = 4 mice per group, Student’s t-test).
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Supplementary Videos S1 and S2). There was no significant 
difference in survival between scrambled-siPTEN and SMNΔ7 
controls.
Treated SMNΔ7 mice display improved motor 
function
The motor function of these mice was assessed daily by perform-
ing a righting reflex test. The mice were placed on their backs 
and given 30 seconds to readjust themselves onto their paws. If 
they were able to achieve the upright posture within the allocated 
time, they were deemed successful. The number of successful mice 
increased steadily in the scAAV9-siPTEN group reaching 100% 
by 15 days (Figure 2c). In contrast, scAAV9-scrambled-siPTEN 
controls were rarely able to complete the test, with the highest 
level of success reaching 20% on two nonconsecutive days which 
was very similar to untreated SMNΔ7 mice. For comparison, car-
rier littermates were also tested for their ability to self-right; all 
carriers tested were able to successfully complete the test from 
day 2 onward. This shows a robust improvement in phenotype of 
scAAV9-siPTEN–injected mice over time (Figure 2c).
The rescued mice were assessed daily for any signs of ill health 
as well as for body weight and motor function. The tails of the res-
cued mice were clearly shorter and thicker than usual and began 
to display necrosis as the animals aged. Furthermore, the ears of 
these animals became red and inflamed before displaying signs of 
necrosis too. This phenotype has previously been reported in res-
cued SMA mice and is thought to be a part of the disease process 
rather than an effect of the treatment.27–31 Furthermore, extremity 
Figure 2 A single scAAV9-siPTEN injection improves weight gain and extends the lifespan of the SMNΔ7 mouse model of SMA. (a) Images 
showing the same SMNΔ7 pups at different ages as indicated; for reference, a gender-matched carrier littermate was included. The pups were 
injected at postnatal day 1 with either scAAV9-siPTEN or scAAV9-scrambled-siPTEN. (b) Body weight increase in SMNΔ7 mice injected with scAAV9-
siPTEN or scAAV9-scrambled-siPTEN from postnatal days 2–20. Body weight of scAAV-siPTEN injected mice was significantly greater than that of 
scAAV9-scrambled-siPTEN mice from day 11 onward (P < 0.05 two-way ANOVA with Bonferroni post hoc test). Untreated and carrier groups were 
included as controls. (c) Percentage of mice able to complete the righting reflex test. Mice were placed on their backs and were deemed successful 
if they were able to reorientate within 30 seconds. scAAV9-siPTEN–injected mice improved gradually over the first 15 days, by which time all mice 
were able to complete the test. (d) Kaplan–Meier cumulative survival curves in the different experimental groups. scAAV9-siPTEN–treated mice lived 
significantly longer than scAAV9-scrambled-siPTEN or SMNΔ7 controls (P < 0.01).
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necrosis has also been reported in two patients suffering from 
severe SMA.32 As the mice aged, they began to display reduced 
provoked behavior alongside lack of grooming and a very slight 
reduction in weight and were therefore humanely culled at this 
point. All mice were still able to perform the righting reflex at this 
point but did show evidence of hind limb weakness and muscle 
wasting. It is thus unlikely that the described moribund appear-
ance of the mice was due to motor impairment but rather to some 
other unidentified cause.
scAAV9-mediated siRNA delivery reduces PTEN 
expression in spinal cord motor neurons
Systemic injection of high titer AAV9 viral vectors has previ-
ously been reported to produce widespread transduction within 
the central nervous system as well as other internal organs.22,33 
Immunofluorescence was used to investigate the level of trans-
duction of motor neurons in the lumbar spinal cord and to deter-
mine the efficiency of the vector for PTEN silencing. The siRNA 
sequence used has been previously reported to successfully silence 
PTEN both in vitro and in vivo,16 the construct also expresses green 
fluorescent protein (GFP) under a cytomegalovirus promoter to 
enable identification of transduced cells. Immunofluorescence 
revealed transduction of motor neurons within the lumbar spi-
nal cord as demonstrated by GFP-positive cells in both scAAV9- 
siPTEN and scAAV9-scrambled-siPTEN–injected animals 
(Figure 3a). To test whether reduced PTEN expression has func-
tional relevance in vivo, we performed immunofluorescence 
experiments to demonstrate accumulation of AKT phosphorylated 
at serine473 (AKT-S473), a well-characterized substrate of PTEN 
phosphatase activity.34 Remarkably, motor neurons transduced 
Figure 3 RNAi-mediated reduction in PTEN expression in SMNΔ7 transgenic mice after scAAV9-siPTEN gene transfer to motor neurons. 
Immunofluorescence showing a reduction in PTEN expression in scAAV9-siPTEN-transduced motor neurons as revealed by antibodies against PTEN 
(blue) (a,b), CGRP (red, a), and GFP (green, a,b) compared with scAAV9-ssiPTEN controls. (b) PTEN knockdown results in increased immunolabelling 
phosphorylated-AKT (red) in scAAV9-siPTEN-transduced motor neurons (green). Bar = 20 µm. scAAV-mediated PTEN knockdown improves motor 
neuron survival in SMNΔ7 mice. (c) Quantification of CGRP-positive cells in siPTEN or scrambled-siPTEN transduced lumbar spinal cord sections, 
showing the average number of motor neurons per section in 12 sections per animal. (d) GFP-positive CGRP neuron count. (e) GFP-negative CGRP 
neuron count. **P < 0.01; n = 3; Student’s t-test.
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with scAAV9-siPTEN displayed reduced PTEN expression and 
increased phospho-AKT-S473 fluorescence compared to those of 
scAAV9-scambled-siPTEN controls (Figure 3b).
scAAV9-siPTEN is associated with increased motor 
neuron survival
We hypothesized that the effect on survival and phenotype seen 
after scAAV9-siPTEN delivery was due to increased survival of 
motor neurons. To assess motor neuron survival, lumbar spinal 
cord sections were stained for the motor neuron–specific marker 
calcitonin gene-related peptide (CGRP) (Figure 3a). Counting 
the number of CGRP-positive cells in lumbar spinal cord sections 
revealed a significant increase in motor neurons in spinal cord 
sections of scAAV9-siPTEN–injected mice compared to scAAV9-
scrambled-siPTEN–injected controls (Figure 3c). Analysis of 
GFP-positive motor neurons revealed that the increase in total 
motor neuron number (Figure 3c) was due to an increase in 
GFP-positive motor neurons (Figure 3d) as the number of GFP 
negative motor neurons was not significantly different between 
siPTEN and scrambled-siPTEN groups (Figure 3e).
scAAV9-mediated siRNA delivery reduces PTEN 
expression in skeletal and heart muscles
scAAV9 has been shown to transduce many organs following 
intravenous injection, including skeletal and heart muscle.12–14 
This may be of direct therapeutic relevance for SMA as cardiac 
defects have also been reported in SMA patients and mouse mod-
els.4,12–14 We therefore used immunofluorescence to investigate the 
level of AAV9-mediated transduction in cardiac tissue; actin was 
labeled with rhodamine phalloidin (red), nuclei were labeled with 
Hoechst (blue), and GFP expression identified scAAV9-siPTEN-
transduced cells. Immunofluorescence analysis revealed wide-
spread transduction of cardiac cells.
To explore the impact of PTEN depletion on downstream path-
ways, we performed western blotting experiments in skeletal muscle 
to determine levels of AKT phosphorylated at serine473 (AKT-
S473), a well-characterized substrate of PTEN phosphatase activity.31 
Indeed, skeletal muscles from mice injected with scAAV9-siPTEN 
displayed reduced PTEN expression and increased phospho-AKT-
S473 compared to those of scAAV9-scambled-siPTEN controls 
(Figure 4b,d,e). The level of PTEN and phosphorylated AKT was 
similar in wild type and untreated SMA mice (Figure 4b,d,e). 
Interestingly, SMN protein levels were unchanged in scAAV9-
siPTEN mice compared to controls. Similarly, reduced PTEN 
expression and increased AKT and S6K phosphorylation were also 
observed in heart muscles of mice injected with scAAV9-siPTEN 
(Figure 4f,g,h); however, no significant change was seen in phos-
phorylation of MAPK (Figure 4i).
DISCUSSION
We have previously shown that depleting PTEN protein levels 
improves survival and growth cone size in cultured primary Smn-/- 
motor neurons.16 Furthermore, intramuscular administration of 
AAV6-siPTEN to an SMA mouse model resulted in the successful 
targeting of motor neurons.16 Here, we demonstrate that systemic 
targeting of PTEN using viral vectors reduces disease severity and 
modestly improves survival in a mouse model of severe SMA.
To investigate the potential effectiveness of PTEN silencing 
as a therapeutic strategy for SMA, we first administered AAV6-
siPTEN by intramuscular injection to the LAL muscle of SMNΔ7 
mice in order to investigate its impact on NMJ pathology. As 
expected, AAV6-scrambled-siPTEN–treated animals displayed a 
reduced number of fully innervated NMJs in the caudal band of 
the LAL.11 In stark contrast, muscles from animals injected with 
AAV6-siPTEN had significantly higher numbers of intact NMJs. 
Thus, a single injection of AAV6-siPTEN was sufficient to reduce 
PTEN levels in motor neurons16 and was also able to have a direct 
impact on one of the earliest pathological events occurring in the 
neuromuscular system during the disease course of SMA. These 
findings therefore confirm the presence of a postnatal therapeu-
tic time-window in SMA mice and show that during this window 
NMJ pathology can be ameliorated.35
These findings prompted us to investigate whether systemic 
depletion of PTEN could have a more substantial impact on the 
overall disease severity and lifespan of SMNΔ7 mice. AAV9 has 
previously been successfully used to deliver gene therapy for 
SMA,22,28,30 and we therefore generated an AAV9 vector express-
ing siPTEN to systemically silence PTEN. We found that a single 
injection of scAAV9-siPTEN significantly increased lifespan in 
SMA mice, with a threefold increase in mean survival compared 
to scAAV9-scrambled-siPTEN controls. Although the scAAV9-
siPTEN–treated mice were smaller than their carrier littermates, 
their bodyweight increased steadily and became significantly 
greater than that of scAAV9-scrambled-siPTEN mice at day 
11. Moreover, scAAV9-siPTEN–treated mice showed a gradual 
improvement in their ability to self-right over the first 2 weeks 
of their life, and by 15 days, 100% of treated animals were able to 
complete the test. The ability to self-right was then maintained 
throughout life. In comparison, scAAV9-ssiPTEN controls acted 
much like SMNΔ7 mice, with a maximum of 20% of animals com-
pleting the test.
A positive effect of PTEN depletion on neuronal survival 
has previously been demonstrated following transplantation of 
PTEN-deficient dopamine neurons into a Parkinson’s mouse 
model,36 where PTEN-deficient neurons were less susceptible to 
cell death than controls. These findings correlate well with the 
data presented here showing that systemic depletion of PTEN can 
improve survival of spinal cord motor neurons in a mouse model 
of SMA. Depletion of PTEN has also been shown to enhance 
regeneration of corticospinal axons following spinal cord injury,37 
demonstrating that PTEN depletion can also promote axon 
growth in vivo. Furthermore, deletion of PTEN combined with 
deletion of SOCS3 promotes axon regeneration in adult retinal 
ganglion cells following crush injury.20,38 Our previous studies also 
revealed that activation of the mTOR pathway was sufficient to 
trigger protein translational regulation leading to robust axonal 
growth as assessed by an increase in β-actin protein levels and that 
modulation of the PTEN/mTOR pathway also restores the spe-
cific pathological effects in motor neurons from a mouse model 
of SMA.16
There is a risk, from a therapeutic perspective, that PTEN 
knockdown could result in broad alteration of normal cellular 
activities, with the potential for tumorigenesis and/or disruption 
of normal neuronal function. However, the use of vectors targeted 
274 www.moleculartherapy.org vol. 23 no. 2 feb. 2015
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specifically to motor neurons, by using cell-specific promoters or 
by using a Tet on/off inducible system to finely tune PTEN knock-
down, is one way to potentially overcome these issues without 
increased risk of tumorigenesis. Furthermore, the siRNA used 
in this study has been previously shown to achieve around 60% 
reduction in PTEN expression in motor neurons in  vitro. Since 
this is not a complete depletion of PTEN, it may not be sufficient 
to generate unwanted off-target effects such as tumorigenesis. 
Thus, we speculate that the PTEN approach could be an alterna-
tive/complementary therapeutic strategy for ameliorating motor 
Figure 4 PTEN depletion in the heart and skeletal muscle following systemic delivery of scAAV9-siPTEN in P1 SMNΔ7 transgenic mice. 
(a) Immunofluorescence showing GFP expression in scAAV9-siPTEN-transduced heart cells (GFP, green), Hoechst labeled nuclei (blue), and actin 
(rhodamine phalloidin, red). Bar = 20 µm. (b–e) Western blotting in skeletal muscles. (f–i) Western blotting analysis in heart muscles.
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neuron pathology in SMA through a non–SMN-dependent 
mechanism.
Our data show that systemic depletion of PTEN can modestly 
improve survival in a severe SMA mouse model, suggesting a poten-
tial approach for developing therapies against SMA. Furthermore, 
the improvement in motor neuron survival suggests possible appli-
cations for the treatment of other neurodegenerative diseases.
MATERIALS AND METHODS
Viral vectors. A 19 nucleotide sequence targeting mouse PTEN27 
was subcloned in the scAAV9 genome vector. siPTEN sense 
oligonucleotide 5′-CGCGTCCCCGCCAAA TTTAACTGCAGAGTTCAA 
GAGACTCTGCAGTTAAATTTGGCTTTTTGGAAAT and siPTEN 
antisense oligonucleotide 5′-CGATTTCCAAAAAGCCAAATTTAACTG 
CAGAGTCTCTTGAACTCTGCAGTTAAATTTGGCGGGGA were 
annealed and cloned into the MluI/ClaI-digested vector. In addition, 
a scrambled (ssiPTEN) sense nucleotide 5′-CGCGTCCCCCGCAATATT 
CAATCGAGGATTCAAGAGATCCTCGATTGAATATTGCGTTTTT 
GGAAAT and ssiPTEN antisense nucleotide 5′-CGATTTCCAAAAACG 
CAATATTCAATCG AGGATCTCTTGAATCCTCGATTGAATATTGC 
GGGGGA were used to generate the control scAAV9-ssiPTEN vector. 
High-titer scAAV9 vectors were then prepared using a three-plasmid tran-
sient cotransfection system involving a plasmid encoding the Rep2Cap9 
sequence (pAAV2/9), a helper plasmid (pHelper, Stratagene, La Jolla, CA), 
and the vector genomes (scAAV-siPTEN or scAAV-scrambled-siPTEN).11
Animals and treatment. For all in vivo studies, FVB.
Cg-Tg(SMN2*delta7)4299Ahmb Tg(SMN2)89Ahmb Smn1tm1Msd/J SMNΔ7 
mice (The Jackson Laboratory stock 005025) were used along with car-
rier littermates for controls. All mice were maintained in a controlled facil-
ity in a 12-hour dark-light photocycle with free access to food and water. 
All in vivo experimental work was performed in accordance with the UK 
Home Office Animals (Scientific Procedures) Act 1986. Carrier animals 
were used for breeding, and the offspring were genotyped immediately 
after birth by PCR amplification of the transgenes. Animals were injected 
into the facial vein the day after birth (postnatal day 1) under isoflurane 
anesthesia with 10 µl (1010 vector genome) of either scAAV9-siPTEN (n 
= 10) or scAAV9-scrambled-siPTEN (n = 10). The animals were left to 
recover before being rolled in sawdust from their cage and returned to 
the cage with their mother. No episodes of litter exclusion were observed. 
Littermates were split equally between treatment groups when possible. 
Mice were weighed and assessed for motor ability daily as well as being 
scored for signs of distress. The righting reflex test was used to assess motor 
function as characterized previously.39
Immunohistochemistry. Mice were terminally anesthetized with pento-
barbital and transcardially perfused with phosphate-buffered saline (PBS) 
supplemented with heparin followed by perfusion with 4% paraformalde-
hyde. Relevant organs were collected and postfixed in 4% paraformalde-
hyde for 24 hours at 4 °C. Spinal cords and brains were cryoprotected in 
30% sucrose before being cryoembedded in optimum cutting tempera-
ture medium. Following preparation of 20 µm spinal cord sections using 
a sliding cryostat microtome, triple immunofluorescence was performed 
to assess the reduction of PTEN expression in transduced motor neurons. 
Briefly, sections were stained using a mouse antibody to PTEN (sc-7974, 
Santa Cruz Biotechnology, Dallas, TX) with a goat antimouse IgG Alexa 
Fluor 350 Conjugate (Invitrogen, A11045 Paisley, UK) secondary anti-
body, a rabbit antibody to CGRP with an Alexa Flour 568-conjugated 
goat antirabbit secondary antibody (Invitrogen, A11036) and a goat anti-
body to GFP with a donkey antigoat secondary antibody fluorescein iso-
thiocyanate conjugate (Jackson 705-095-003, West Grove, PA). To assess 
motor neuron survival, lumbar spinal cord sections were stained with a 
rabbit antibody to CGRP with an Alexa 568-conjugated goat antirabbit 
secondary antibody (Invitrogen A11036), and the number of CGRP-
positive cells was counted. The average number of motor neurons per 
section in 12 sections per animal, 3 mice per group were counted in a 
blind manner. Heart muscles were stained with rhodamine phalloidin for 
F-actin (red, 1:200, Life Technologies, Paisley, UK).
Western blot analysis. Fresh skeletal muscles or heart were dissected, snap-
frozen in liquid nitrogen, and stored at −80 °C before analysis. Protein 
extraction for western blotting was performed as described previously.15,16 
Primary antibodies, anti-mouse GAPDH antibody (1:5000; Calbiochem, 
Hertfordshire, UK), anti-rabbit PTEN (1:1000; Cell Signaling, Danvers, 
MA), AKT (1:1000; Cell Signaling), pAKT ser473 (1:1000; Cell Signaling), 
pS6K (1:1000; Cell Signaling), pMAPK(1:1000; Cell Signaling), goat anti-
rabbit or mouse horseradish peroxidase secondary antibodies (1:5,000; 
Cell Signaling) were used.
NMJ pathology. A single intramuscular injection of AAV6 expressing siP-
TEN (1010 viral particle) was delivered to the LAL muscle (from the cranial 
muscle group located between the ears of the mouse) in anesthetized SMA 
mice and control littermates at P1. Following sacrifice at P10, NMJ immu-
nohistochemistry was performed on whole-mount muscle preparations as 
previously described.13 Briefly, the LAL was dissected in 0.1 mol/l PBS before 
exposure to α-bungarotoxin conjugated to tetramethyl-rhodamine isothio-
cyanate (TRITC-a-BTX; 5 mg/ml; Molecular Probes, Paisley, UK) for 10 
minutes and subsequent fixation in 0.1 mol/l PBS containing 4% paraformal-
dehyde (Electron Microscopy Supplies, Hatfield, PA) for 15 minutes. Muscles 
were blocked in 4% bovine serum albumin and 1% Triton X in 0.1 mol/l PBS 
for 30 minutes before incubation with primary antibodies directed against 
150 kDa neurofilament proteins (1:350 dilution; Chemicon International, 
Billerica, MA) overnight, followed by incubation for 4 hours in a 1:40 dilu-
tion of swine antirabbit secondary antibody conjugated to the fluorescent 
label fluorescein isothiocyanate (Dako, Cambridgeshire, UK). Muscles were 
then whole-mounted in Mowoil (Calbiochem) on glass slides before imag-
ing on a laser scanning confocal microscope (40× objective; 0.8NA; Zeiss 
710). A minimum of 50 endplates, selected at random, were assessed in each 
muscle preparation. To assess levels of denervation, the occupancy of indi-
vidual NMJs was evaluated by categorizing endplates as either fully occupied 
(neurofilament entirely overlies endplate), partially occupied (neurofilament 
partially covers endplate), or vacant (no neurofilament overlies endplate). 
Four mice were used for NMJ analysis in each group.
Statistical analysis. Power analysis was conducted using GPower 3.0 
software (Oakland, CA), and statistical analysis was performed using 
GraphPad Prism v5. (La Jolla, CA) Statistical significance was determined 
by one- or two-way analysis of variance depending on individual experi-
ment as stated in figure legends.
SUPPLEMENTARY MATERIAL
Video S1. Video was taken on day 13. The biggest mouse is a litter-
mate control. The medium size one is siPTEN treated. The smallest one 
is scramble (ssiPTEN) treated control.
Video S2. Video was taken on day 34. The bigger mouse is a litter-
mate control. The smaller one is siPTEN treated. No scramble control 
was alive at day 34.
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